HM6A Stock Overview
Operates as a pharmaceutical company in Brazil. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Hypera S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$3.26 |
| 52 Week High | R$5.45 |
| 52 Week Low | R$3.14 |
| Beta | 0.44 |
| 11 Month Change | -27.23% |
| 3 Month Change | -32.37% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -35.45% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| HM6A | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.8% | -1.2% | -0.02% |
| 1Y | n/a | -20.1% | 8.2% |
Return vs Industry: Insufficient data to determine how HM6A performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how HM6A performed against the German Market.
Price Volatility
| HM6A volatility | |
|---|---|
| HM6A Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HM6A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HM6A's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 10,301 | Breno Pires de Oliveira | www.hypera.com.br |
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand.
Hypera S.A. Fundamentals Summary
| HM6A fundamental statistics | |
|---|---|
| Market cap | €2.10b |
| Earnings (TTM) | €259.66m |
| Revenue (TTM) | €1.29b |
8.1x
P/E Ratio1.6x
P/S RatioIs HM6A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HM6A income statement (TTM) | |
|---|---|
| Revenue | R$7.78b |
| Cost of Revenue | R$3.04b |
| Gross Profit | R$4.74b |
| Other Expenses | R$3.17b |
| Earnings | R$1.57b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.48 |
| Gross Margin | 60.95% |
| Net Profit Margin | 20.18% |
| Debt/Equity Ratio | 84.3% |
How did HM6A perform over the long term?
See historical performance and comparison